American journal of clinical oncology
-
Am. J. Clin. Oncol. · Feb 2008
Intra-arterial infusion chemotherapy with 5-fluorouracil and cisplatin in advanced pancreatic cancer: a feasibility study.
Our aim was to examine the efficacy and tolerability of intra-arterial infusion chemotherapy with 5-fluorouracil (5-FU) and cisplatin in advanced pancreatic cancer. ⋯ These results suggest that intra-arterial infusion chemotherapy with 5-FU and cisplatin is tolerable and feasible treatment to improve the prognosis in locally advanced pancreatic cancer patients without distant metastasis.
-
Am. J. Clin. Oncol. · Feb 2008
Randomized Controlled Trial Comparative StudyThere is a wide range of predictive dosimetric factors for I-125 and pd-103 prostate brachytherapy.
We have analyzed biochemical control versus multiple dosimetric parameters for a relatively homogeneous group of low-risk patients treated with I-125 or Pd-103. ⋯ Our demonstration of some predictive value of nearly all dosimetric parameters is in contrast to the impression one is left with from prior reports, which explicitly or implicitly portray a unique role for D90 or V100. We think that it is important for clinical investigators to look at other dosimetric parameters as part of ongoing clinical investigations because it is likely that dosimetric guidelines can be refined to improve our ability to rate implant quality.
-
Am. J. Clin. Oncol. · Feb 2008
Factors that predict the burden of axillary disease in breast cancer patients with a positive sentinel node.
This study identifies clinical and pathologic factors predictive of having > or =4 involved axillary lymph nodes in breast cancer patients with a positive sentinel node. These factors may influence radiation therapy decisions. ⋯ We have identified primary tumor and SLN variables that predict for a greater probability of having a significant burden of residual disease in the axilla that may affect treatment recommendations.
-
Am. J. Clin. Oncol. · Dec 2007
Randomized Controlled TrialImproved survival, quality of life, and quality-adjusted survival in breast cancer patients treated with efaproxiral (Efaproxyn) plus whole-brain radiation therapy for brain metastases.
To determine whether efaproxiral, an allosteric modifier of hemoglobin, improves quality of life and quality of survival in patients with primary breast cancer and brain metastases when used as an adjunct to whole-brain radiation therapy (WBRT). ⋯ Survival, quality of life, and quality-adjusted survival were all improved in breast cancer patients with brain metastases receiving efaproxiral and WBRT compared with those receiving WBRT alone.
-
Am. J. Clin. Oncol. · Dec 2007
Obesity is not predictive of overall survival following permanent prostate brachytherapy.
To evaluate the impact of obesity on cause-specific (CSS), biochemical progression-free (bPFS), and overall survival (OS) following prostate brachytherapy. ⋯ Obesity did not impact CSS, bPFS, or OS in patients treated with permanent prostate brachytherapy. Cardiovascular or pulmonary disease and second malignancies substantially outweighed prostate cancer as competing causes of death.